* Abcellera Biologics Inc ABCL.OQ ABCL.O is expected
to show a
rise in quarterly revenue when it reports results on November
8.
* The Vancouver British Columbia-based company is expected
to
report a 1,260.8% increase in revenue to $74.954 million from
$5.51 million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Abcellera Biologics
Inc
is for earnings of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $32, above its last closing price of $12.11.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.01 -0.02 -0.02 Met -28.5
Mar. 31 2022 0.40 0.38 0.54 Beat 40.6
Dec. 31 2021 0.18 0.19 0.19 Met 0.6
Sep. 30 2021 -0.07 -0.05 -0.08 Missed -52.4
Jun. 0.07 0.08 -0.01 Missed -112.9
30 2021
Mar. 31 2021 0.36 0.38 0.37 Missed -2.2
Dec. 31 2020 0.63 0.61 0.44 Missed -27.9
This summary was machine generated November 4 at 13:50 GMT. All
figures in US dollars unless otherwise stated